The trial for the Corona Virus vaccine has been resumed in the UK by Pharma giant AstraZeneca following a pause caused by a UK volunteer falling ill.
“Clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, have resumed in the UK following confirmation by the Medicines Health Regulatory Authority (MHRA) that it was safe to do so,” the company said in a statement.
On Wednesday, AstraZeneca announced that it had had “voluntarily paused” its trial of the vaccine developed alongside Oxford University after the volunteer developed an unexplained illness.
The AZD1222 vaccine (Corona Virus Vaccine) uses a weakened version of a common cold-causing adenovirus engineered to code for the spike protein that the Covid-19 coronavirus uses to invade cells.
An independent committee thereby was drafted to review the safety as part of a routine step.
The committee “has concluded its investigations and recommended to the MHRA that trials in the UK are safe to resume”, AstraZeneca said.
“The company will continue to work with health authorities across the world and be guided as to when other clinical trials can resume to provide the vaccine broadly, equitably, and at no profit during this pandemic.”